drugset / Trial / NCT05359835

DTPA (Diethylenetriaminepenta-acetate) Chelation for Symptoms After Gadolinium-assisted MRI Exposure

NCT05359835 ↗

Phase 0 Withdrawn Stanford University
NaSingle-groupOpen-labelTreatment

Summary

The study aims at gathering additional data on the safety and effectiveness of using intravenous administration of the drugs Ca-DTPA/Zn-DTPA to remove the heavy metal gadolinium from the bodies of patients who have retained it and developed symptoms of Gadolinium Deposition Disease following an MRI in which a gadolinium-containing contrast agent was utilized. The outcome data will include measures of symptom relief after as many as six paired Calcium-DTPA/Zinc-DTPA chelation treatments. The study also aims at gathering additional data before and after DTPA treatment regarding levels of certain cytokines in the patients' blood that have been reported to be abnormally elevated in patients with retained gadolinium.

Timeline

Start
2023-04-11
Primary completion
2024-09-12
Completion
2024-09-13

Outcome

Outcome not reported

Stopped (Enrollment): “Could not recruit subjects quickly enough”

Drugs

EvaluationDrugModalityDoseRoute
Subject Calcium DTPA Unknown 500 mg Intravenous
Subject Zinc DTPA Small molecule 500 mg Intravenous

Indications

No indication recorded.